| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-10-02 | Servier (France) Xention (UK) | XEN-D0103 | atrial fibrillation | R&D |
Cardiovascular diseases | R&D agreement |
| 2013-10-01 | Epigenomics (Germany) Polymedco (USA) | Epi proColon® (colorectal cancer blood test) | colorectal cancer | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2013-10-01 | MDX Health (Belgium) FedMed (USA) ACPN (USA) | ConfirmMDx™ for prostate cancer test | prostate cancer | distribution |
Cancer - Oncology | Distribution agreement |
| 2013-09-30 | UCB (Belgium) Vectura (UK) | biologic immunomodulatory product | severe inflammatory respiratory disease | R&D |
Inflammatory diseases - Respiratory diseases | R&D agreement |
| 2013-09-27 | Sanofi (France) Aviesan (France) | R&D |
Rare diseases | R&D agreement | ||
| 2013-09-26 | 4SC (Germany) Panoptes Pharma (Austria) | PP-001 | uveitis, viral conjunctivitis | development |
Ophtalmological diseases | Development agreement |
| 2013-09-26 | Ablynx (Belgium) Merck KGaA, Merck Serono (Germany) | Nanobodies against a number of targets across multiple disease areas | R&D |
Cancer - Oncology - Immunological diseases - Neurological diseases | R&D agreement | |
| 2013-09-26 | LFB Biomanufacturing, Laboratoire français du fractionnement et des biotechnologies (France) Hemarina (France) | HEMO2life® | bioproduction |
Transplantation | Production agreement | |
| 2013-09-26 | Adimab (USA) NovoNordisk (Denmark) | antibody platform | licensing |
Technology - Services | Licensing agreement | |
| 2013-09-25 | Apeiron Biologics (Austria) Idis (UK - USA) | Managed Access Program for APN311 | high-risk neuroblastoma | collaboration |
Cancer - Oncology | Services contract |
| 2013-09-25 | AstraZeneca (UK) Labcyte (USA) | Echo® acoustic liquid handling system | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-09-23 | Ablynx (Belgium) AbbVie (USA -IL) | ALX-0061 | rheumatoid arthritis, systemic lupus erythematosus | licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2013-09-23 | Karo Bio (Sweden) - 4D Science (Germany) | validation of a nuclear receptor as a target in fibrosis | fibrotic diseases | R&D |
R&D agreement | |
| 2013-09-23 | Neurolixis (USA) Pierre Fabre Médicament (France) | F15599 and befiradol | Parkinson's disease, Rett syndrome | licensing |
Neurodegenerative diseases - Neurodevelopmental diseases - Rare diseases | Licensing agreement |
| 2013-09-23 | Telormedix (Switzerland) Molecular Profiles (UK), a subsidiary of Columbia Laboratories (USA) | TMX-302 | psoriasis | development |
Autoimmune diseases – Dermatological diseases | Production agreement |
| 2013-09-23 | MidaSol™ Therapeutics (UK) undisclosed major US pharmaceutical company (USA) | GNP and PharmaFilm® technologies | undisclosed | R&D |
undisclosed | R&D agreement |
| 2013-09-19 | Activiomics (UK) Kyowa Hakko Kirin (Japan) | TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform | R&D |
Technology - Services | R&D agreement | |
| 2013-09-19 | Sanofi (France) University of Massachusetts Boston’s College of Science and Mathematics (CSM) (USA - MA) | Establishment of a new subsidiary in the EU | ||||
| 2013-09-19 | Boehringer Ingelheim (Germany) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) | companion diagnostic tests | development |
Cancer - Oncology | Development agreement | |
| 2013-09-18 | Medivir (Sweden) Ferrer (Spain) | Adasuve® (Staccato® Loxapine) | schizophrenia, bipolar disease | licensing |
CNS diseases - Mental diseases | Licensing agreement |
